Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $143.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 66.27% year-over-year to $143.5 million in Q1 2026; TTM through Mar 2026 was $143.5 million, a 66.27% increase from a year earlier, with the FY2025 full-year figure at $135.7 million, up 68.33% from the prior year.
• Total Current Liabilities advanced to $143.5 million in Q1 2026 per TARS's latest filing, from $135.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $143.5 million in Q1 2026 and bottomed at $11.7 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $42.5 million (2024), against an average of $56.2 million.
• Across the five-year window, Total Current Liabilities advanced 5.11% in 2023 and surged 249.28% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $15.4 million in 2022, then surged by 139.39% to $36.9 million in 2023, then soared by 118.25% to $80.6 million in 2024, then jumped by 68.33% to $135.7 million in 2025, then rose by 5.76% to $143.5 million in 2026.
• Per Business Quant, the three latest TARS Total Current Liabilities figures stand at $143.5 million (Q1 2026), $135.7 million (Q4 2025), and $117.0 million (Q3 2025).